
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical Inc. demonstrated robust performance with a 31% year-over-year increase in net revenue to $209.4 million, exceeding both internal forecasts and consensus estimates. The company's flagship product, Jornay, exhibited strong growth with total prescriptions increasing by 20% year-over-year, contributing to significant revenue growth of 28.2% sequentially, driven by improvements in gross-to-net metrics. Additionally, management raised its 2025 revenue guidance, projecting revenues between $745 million and $760 million, indicating a strong outlook for future financial performance within the specialty pharmaceutical sector.
Bears say
Collegium Pharmaceutical Inc faces several fundamental challenges that contribute to a negative outlook on its stock. Sales for key products, including Xtampza ER and Belbuca, have shown a downward trend with prescription decreases in recent quarters, leading to concerns about overall revenue growth. Additionally, the company is at risk from potential generic competition, unfavorable reimbursement dynamics, and execution risks, which could adversely impact its commercial trajectory and profitability in the future.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares